Fig 2: Nomogram for predicting 1-, 3- and 5-year mortality in association with PTRF expression and clinical data. A Nomogram of all grades of glioma patients in CGGA dataset. B Nomogram of GBM patients in CGGA dataset. C The calibration curve for predicting patient survival of all grades of glioma patients in CGGA dataset. D The calibration curve for predicting patient survival of GBM patients in CGGA dataset

Fig 3: Downregulation of Cavin-1 in nail and pustular psoriasis samples. Expression and localization of Cavin-1 were compared with those in location-matched normal skin/nail samples, with expression quantified as a percentage of positive viable epidermal keratinocytes relative to that of location-matched control (bar = 100 μm). Each point in the bar represents an individual case, with bar graphs presented as mean ± SD from 3 independent immunostaining experiments error (2-way ANOVA: ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗P < .0001).

Fig 4: Mutational profile of glioma with high and low expression of PTRF

Fig 5: PTRF is highly expressed in microvascular proliferation (MVP) regions and MES tumor cells. A Expression of PTRF in different histological regions of GBM in Ivy dataset. B The single-cell data showed that PTRF was highly expressed in tumor cells. C Expression of PTRF in different glioma cellular states